Press Release Description

Immune Checkpoint Inhibitor Market Reaches USD 51.2 Billion in 2023, Expected CAGR of 15.6% till 2030

The Global Immune Checkpoint Inhibitor Market size was valued at USD 51.2 billion in 2023 and is projected to grow at a CAGR of 15.6% during the forecast period of 2025-30, cites MarkNtel Advisors in the recent research report. Immune checkpoint inhibitors are a part of the immune system. They work by releasing a natural brake on a human immune system so that the immune cells also known as ‘T cells’ identify and attack tumors. There are various reasons behind the expansion of the industry. One of the main drivers of the industry is the surge in the number of cancer cases. On a yearly basis, there are millions of new diagnoses are done by doctors. Thus, there is a rising requirement for some effective treatments.

Additionally, the constantly increasing awareness among patients correlates with the benefits of immune checkpoint inhibitors like less negative effects and targeted therapeutic effects is another prominent reason that is propelling the demand for these inhibitors in the world. However, because of massive expenses associated with the R&D, as well as the lack of knowledge and awareness among individuals for utilizing these immune inhibitors hinder the extension of these inhibitors market across the world, further states the research report, “Global Immune Checkpoint Inhibitors Market Analysis, 2024.”

Global Immune Checkpoint Inhibitors Market

Global Immune Checkpoint Inhibitors Market Segmentation Analysis

PD-1 Inhibitors Expected to Lead the Global Immune Checkpoint Inhibitor Industry with a Prominent Market Share

Based on the Drug Class segment, the market is further bifurcated into the following segments:

  • PD- 1
    • Opdivo (Nivolumab)
    • Keytruda (Pembrolizumab)
  • PD- L1
    • Tecentriq (Atezolizumab)
    • Bavencio (Avelumab)
    • Imfinzi (Durvalumab)
  • CTLA- 4
    • Yervoy (Ipilimumab)

Out of these, the segment that is expected to obtain the largest share in the Global Immune Checkpoint Inhibitor Industry is PD-1 Inhibitors. It is mainly accredited due to the huge investment made by the government in the R&D activities for bringing transformation in PD-1 inhibitors such as Keytruda and Opdivo, combined with quick approval from the regulatory association.

Besides, the approval of Pembrolizumab by the Food & Drug Association (FDA) owing to its productivity in addressing indications including – Head & Neck Squamous Cell Cancer, Non–Small Cell Lung Cancer, Melanoma, and others, the demand for PD-1 inhibors has extended rapidly, i.e., playing a notable role in the expansion the overall growth of the industry. Additionally, cases of allergic reactions from different drugs including Yeryoy, and CTLA-4 inhibitor, is another significant factor leading to higher inclination of patients towards PD-1, and consequently promoting the extension of the checkpoint inhibitors across the world.

North America Leads the Global Immune Checkpoint Inhibitor Industry

Globally, the Immune Checkpoint Inhibitors industry extends across:

  • North America
  • South America
  • Europe
  • Middle East & Africa
  • Asia-Pacific

The region that dominates the Global Immune Checkpoint Inhibitor Market is North America. It is augmented due to the increasing commonness of several types of cancers in the region. Moreover, improved healthcare infrastructure and vigorous R&D activities also fuel the growth of the industry. Also, the surge in the presence of dominating pharmaceutical companies along with the availability of innovative treatments for cancer further thrives the industry growth. Additionally, the policies imposed by the North American government, and substantial investments in cancer research contributes to the constantly increasing adoption of immune checkpoints in the entire North American region. Plus, the leadership in the industry of the region highlights the key role in advancing the cancer treatment.

Competitive Landscape

With strategic initiatives such as mergers, collaborations, and acquisitions, the leading market players, including - AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bluebird Bio, Inc., Bristol Myers Squibb, CARsgen Therapeutics, Eli Lilly and Company, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., and others. are looking forward to strengthening their market positions.

Key Questions Answered in the Research Report

  1. What are the industry’s overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares)?
  2. What are the trends influencing the current scenario of the market?
  3. What key factors would propel and impede the industry across the region?
  4. How has the industry been evolving in terms of geography & product adoption?
  5. How has the competition been shaping across various regions?
  6. How have buying behavior, customer inclination, and expectations from product manufacturers been evolving during 2020-30?
  7. Who are the key competitors, and what strategic partnerships or ventures are they coming up with to stay afloat during the projected time frame?

Place an order
Only market data will be provided in the excel spreadsheet.

USD 3,700
USD 2,960

The report will be delivered in PDF format without printing rights. It is advised for a single user.

USD 4,850
USD 3,880

The report will be delivered in PDF format with printing rights. It is advised for up to five users.

USD 6,000
USD 4,800

The report will be delivered in PDF format with printing rights and excel sheet. It is advised for companies where multiple users would like to access the report from multiple locations

USD 7,500
USD 5,250

Need Assistance?

WRITE AN EMAIL

[email protected]
100% Safe & Secure

Strongest encryption on the website to make your purchase safe and secure